| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 168 | 2026 | 1406 | 13.710 |
Why?
|
| Prostate | 53 | 2022 | 402 | 5.690 |
Why?
|
| Gene Expression Regulation, Neoplastic | 72 | 2026 | 2010 | 4.410 |
Why?
|
| Fibroblast Growth Factors | 17 | 2017 | 171 | 2.360 |
Why?
|
| Prostatic Hyperplasia | 18 | 2016 | 108 | 2.270 |
Why?
|
| Cell Line, Tumor | 81 | 2026 | 3714 | 2.130 |
Why?
|
| Receptors, Androgen | 29 | 2022 | 407 | 1.760 |
Why?
|
| Receptors, Fibroblast Growth Factor | 16 | 2021 | 57 | 1.690 |
Why?
|
| Biomarkers, Tumor | 31 | 2025 | 1586 | 1.640 |
Why?
|
| Oncogene Proteins, Fusion | 6 | 2020 | 237 | 1.580 |
Why?
|
| Cell Proliferation | 49 | 2026 | 2463 | 1.560 |
Why?
|
| Adenocarcinoma | 23 | 2026 | 965 | 1.480 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 8 | 2025 | 104 | 1.470 |
Why?
|
| Genes, Tumor Suppressor | 11 | 2017 | 197 | 1.460 |
Why?
|
| Proto-Oncogene Proteins c-akt | 15 | 2021 | 479 | 1.420 |
Why?
|
| Signal Transduction | 47 | 2025 | 4656 | 1.390 |
Why?
|
| Male | 223 | 2026 | 64397 | 1.370 |
Why?
|
| MicroRNAs | 17 | 2021 | 882 | 1.350 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 11 | 2017 | 68 | 1.310 |
Why?
|
| DNA Methylation | 20 | 2026 | 1081 | 1.300 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 4 | 7 | 2016 | 13 | 1.270 |
Why?
|
| Homeodomain Proteins | 7 | 2017 | 558 | 1.260 |
Why?
|
| Phosphoric Monoester Hydrolases | 9 | 2021 | 97 | 1.230 |
Why?
|
| Mice | 105 | 2026 | 18172 | 1.180 |
Why?
|
| Transcription Factors | 18 | 2020 | 2404 | 1.140 |
Why?
|
| Neoplasm Proteins | 16 | 2019 | 679 | 1.130 |
Why?
|
| PTEN Phosphohydrolase | 21 | 2021 | 248 | 1.120 |
Why?
|
| Animals | 128 | 2026 | 33698 | 1.120 |
Why?
|
| RNA, Small Interfering | 8 | 2019 | 662 | 1.050 |
Why?
|
| RNA, Messenger | 24 | 2023 | 2553 | 1.050 |
Why?
|
| Fibroblast Growth Factor 2 | 8 | 2008 | 47 | 1.030 |
Why?
|
| Carcinogenesis | 9 | 2023 | 336 | 1.020 |
Why?
|
| Gene Expression Profiling | 23 | 2018 | 1804 | 1.000 |
Why?
|
| Humans | 234 | 2026 | 130154 | 0.960 |
Why?
|
| Epithelial Cells | 24 | 2022 | 907 | 0.960 |
Why?
|
| Stromal Cells | 20 | 2019 | 316 | 0.890 |
Why?
|
| Immunohistochemistry | 27 | 2020 | 1592 | 0.850 |
Why?
|
| Serine Endopeptidases | 6 | 2020 | 197 | 0.830 |
Why?
|
| Mice, SCID | 19 | 2023 | 585 | 0.820 |
Why?
|
| Transfection | 20 | 2017 | 961 | 0.800 |
Why?
|
| Disease Progression | 30 | 2019 | 2193 | 0.770 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 12 | 2017 | 41 | 0.710 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 26 | 2015 | 1205 | 0.710 |
Why?
|
| Tumor Suppressor Proteins | 8 | 2019 | 484 | 0.690 |
Why?
|
| Genes | 6 | 2010 | 308 | 0.680 |
Why?
|
| Mice, Transgenic | 32 | 2022 | 2329 | 0.680 |
Why?
|
| Prostate-Specific Antigen | 16 | 2024 | 222 | 0.670 |
Why?
|
| Epithelium | 6 | 2023 | 336 | 0.670 |
Why?
|
| Phosphatidylinositol 3-Kinases | 7 | 2021 | 336 | 0.660 |
Why?
|
| Up-Regulation | 20 | 2022 | 824 | 0.650 |
Why?
|
| Tumor Microenvironment | 11 | 2024 | 708 | 0.640 |
Why?
|
| RNA Interference | 8 | 2017 | 491 | 0.630 |
Why?
|
| Neoplasm Recurrence, Local | 16 | 2022 | 1267 | 0.630 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 4 | 2017 | 137 | 0.630 |
Why?
|
| Transcriptional Regulator ERG | 9 | 2020 | 40 | 0.620 |
Why?
|
| Membrane Proteins | 13 | 2013 | 1588 | 0.590 |
Why?
|
| Neoplasm Metastasis | 17 | 2020 | 714 | 0.590 |
Why?
|
| Urinary Bladder Neoplasms | 5 | 2025 | 479 | 0.580 |
Why?
|
| Gene Knockdown Techniques | 9 | 2019 | 378 | 0.580 |
Why?
|
| Chromosomes, Human, Pair 10 | 6 | 1998 | 67 | 0.580 |
Why?
|
| Benzamides | 4 | 2021 | 125 | 0.580 |
Why?
|
| Oncogenes | 3 | 2016 | 163 | 0.570 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2019 | 116 | 0.570 |
Why?
|
| Tumor Cells, Cultured | 18 | 2021 | 975 | 0.540 |
Why?
|
| SOXB1 Transcription Factors | 4 | 2021 | 57 | 0.530 |
Why?
|
| Growth Substances | 5 | 2001 | 99 | 0.530 |
Why?
|
| Tissue Array Analysis | 9 | 2019 | 136 | 0.530 |
Why?
|
| Phosphoproteins | 5 | 2012 | 448 | 0.530 |
Why?
|
| Proto-Oncogene Proteins | 8 | 2021 | 598 | 0.530 |
Why?
|
| RNA-Binding Proteins | 1 | 2021 | 534 | 0.520 |
Why?
|
| Disease Models, Animal | 20 | 2022 | 4646 | 0.520 |
Why?
|
| Oncogene Protein v-akt | 1 | 2017 | 32 | 0.520 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2017 | 39 | 0.520 |
Why?
|
| RGS Proteins | 1 | 2017 | 47 | 0.510 |
Why?
|
| Tumor Burden | 6 | 2017 | 237 | 0.500 |
Why?
|
| Cell Movement | 14 | 2018 | 875 | 0.500 |
Why?
|
| Apoptosis | 27 | 2021 | 1830 | 0.490 |
Why?
|
| Alternative Splicing | 5 | 2011 | 310 | 0.490 |
Why?
|
| Blotting, Western | 14 | 2016 | 1013 | 0.480 |
Why?
|
| Piperazines | 2 | 2021 | 269 | 0.480 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Kinase | 4 | 2025 | 54 | 0.480 |
Why?
|
| Mice, Nude | 15 | 2016 | 699 | 0.470 |
Why?
|
| DNA-Binding Proteins | 8 | 2020 | 1933 | 0.470 |
Why?
|
| Neoplastic Stem Cells | 5 | 2016 | 330 | 0.470 |
Why?
|
| Cell Division | 16 | 2007 | 718 | 0.470 |
Why?
|
| Anti-HIV Agents | 3 | 2023 | 348 | 0.460 |
Why?
|
| Deoxyguanosine | 1 | 2015 | 11 | 0.460 |
Why?
|
| Carcinoma | 5 | 2010 | 283 | 0.460 |
Why?
|
| Cellular Senescence | 4 | 2014 | 217 | 0.460 |
Why?
|
| Interleukin-8 | 3 | 2014 | 200 | 0.450 |
Why?
|
| Cell Transformation, Neoplastic | 11 | 2022 | 588 | 0.450 |
Why?
|
| Pyrroles | 1 | 2017 | 189 | 0.450 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 14 | 2018 | 993 | 0.450 |
Why?
|
| Pyrazoles | 2 | 2021 | 354 | 0.450 |
Why?
|
| Gene Fusion | 5 | 2020 | 57 | 0.440 |
Why?
|
| Pyrimidines | 2 | 2026 | 454 | 0.440 |
Why?
|
| RANK Ligand | 3 | 2022 | 52 | 0.440 |
Why?
|
| Neoplasms | 9 | 2023 | 2980 | 0.430 |
Why?
|
| GTP-Binding Proteins | 3 | 2012 | 157 | 0.430 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2023 | 747 | 0.420 |
Why?
|
| NF-kappa B | 7 | 2022 | 439 | 0.420 |
Why?
|
| DNA Mutational Analysis | 4 | 2017 | 777 | 0.420 |
Why?
|
| GTPase-Activating Proteins | 2 | 2012 | 83 | 0.420 |
Why?
|
| Neoplasm Transplantation | 10 | 2018 | 358 | 0.420 |
Why?
|
| Trans-Activators | 8 | 2015 | 695 | 0.410 |
Why?
|
| Urinary Bladder Neck Obstruction | 1 | 2014 | 25 | 0.410 |
Why?
|
| Neovascularization, Pathologic | 6 | 2018 | 227 | 0.390 |
Why?
|
| Prostatectomy | 13 | 2022 | 304 | 0.390 |
Why?
|
| Neoplasm Invasiveness | 12 | 2025 | 630 | 0.380 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2021 | 1000 | 0.380 |
Why?
|
| Transforming Growth Factor beta | 7 | 2019 | 450 | 0.380 |
Why?
|
| RNA, Neoplasm | 5 | 2018 | 125 | 0.380 |
Why?
|
| Stem Cells | 7 | 2019 | 704 | 0.370 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 3 | 2025 | 95 | 0.370 |
Why?
|
| Epithelial-Mesenchymal Transition | 6 | 2021 | 254 | 0.370 |
Why?
|
| Mitochondria | 4 | 2026 | 768 | 0.370 |
Why?
|
| Alleles | 7 | 2011 | 1675 | 0.370 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 6 | 2004 | 146 | 0.370 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 9 | 2015 | 783 | 0.370 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2025 | 816 | 0.360 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 614 | 0.360 |
Why?
|
| Receptors, G-Protein-Coupled | 8 | 2010 | 292 | 0.360 |
Why?
|
| Paracrine Communication | 3 | 2001 | 67 | 0.350 |
Why?
|
| CpG Islands | 8 | 2023 | 337 | 0.350 |
Why?
|
| Nerve Tissue Proteins | 7 | 2023 | 1076 | 0.350 |
Why?
|
| Phosphorylation | 10 | 2025 | 1571 | 0.350 |
Why?
|
| Cell Cycle Proteins | 5 | 2016 | 705 | 0.350 |
Why?
|
| Nuclear Proteins | 6 | 2017 | 1207 | 0.350 |
Why?
|
| Serum Response Factor | 1 | 2011 | 30 | 0.340 |
Why?
|
| Laryngeal Neoplasms | 3 | 2016 | 85 | 0.330 |
Why?
|
| Proteogenomics | 2 | 2025 | 111 | 0.320 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2010 | 141 | 0.310 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 1332 | 0.310 |
Why?
|
| Androgens | 7 | 2016 | 245 | 0.300 |
Why?
|
| Polymerase Chain Reaction | 10 | 2015 | 1454 | 0.300 |
Why?
|
| Cytokines | 2 | 2022 | 1342 | 0.300 |
Why?
|
| Carrier Proteins | 5 | 2023 | 997 | 0.300 |
Why?
|
| Proto-Oncogene Proteins c-myc | 4 | 2017 | 186 | 0.290 |
Why?
|
| Heterografts | 4 | 2018 | 189 | 0.290 |
Why?
|
| Mice, Inbred C57BL | 18 | 2019 | 4693 | 0.290 |
Why?
|
| Mutation | 14 | 2017 | 6070 | 0.280 |
Why?
|
| Transcription, Genetic | 9 | 2019 | 1364 | 0.280 |
Why?
|
| Protein Isoforms | 5 | 2012 | 422 | 0.280 |
Why?
|
| Cell Differentiation | 13 | 2023 | 1910 | 0.280 |
Why?
|
| Cell Cycle | 9 | 2014 | 594 | 0.280 |
Why?
|
| Down-Regulation | 10 | 2015 | 647 | 0.280 |
Why?
|
| Transcriptome | 5 | 2023 | 1104 | 0.270 |
Why?
|
| Head and Neck Neoplasms | 3 | 2023 | 635 | 0.270 |
Why?
|
| DNA Repair | 3 | 2026 | 570 | 0.270 |
Why?
|
| Promoter Regions, Genetic | 11 | 2019 | 1209 | 0.270 |
Why?
|
| Middle Aged | 36 | 2025 | 28331 | 0.260 |
Why?
|
| Mutation, Missense | 1 | 2012 | 922 | 0.260 |
Why?
|
| Gene Expression | 6 | 2016 | 1481 | 0.260 |
Why?
|
| Protein Kinases | 3 | 2022 | 313 | 0.250 |
Why?
|
| HIV Infections | 3 | 2023 | 2040 | 0.250 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2019 | 63 | 0.250 |
Why?
|
| Androgen Antagonists | 6 | 2018 | 104 | 0.250 |
Why?
|
| Dinucleoside Phosphates | 1 | 2006 | 12 | 0.250 |
Why?
|
| Lung Neoplasms | 5 | 2022 | 1546 | 0.250 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2020 | 260 | 0.240 |
Why?
|
| Receptors, Odorant | 1 | 2006 | 33 | 0.240 |
Why?
|
| Racemases and Epimerases | 1 | 2006 | 12 | 0.240 |
Why?
|
| Gene Expression Regulation | 11 | 2016 | 2323 | 0.240 |
Why?
|
| Glucuronidase | 3 | 2018 | 32 | 0.240 |
Why?
|
| Nanofibers | 1 | 2026 | 17 | 0.240 |
Why?
|
| Cells, Cultured | 10 | 2019 | 2887 | 0.240 |
Why?
|
| Cell Survival | 11 | 2016 | 832 | 0.240 |
Why?
|
| Mice, Inbred NOD | 8 | 2023 | 300 | 0.240 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2016 | 37 | 0.240 |
Why?
|
| Real-Time Polymerase Chain Reaction | 7 | 2020 | 527 | 0.240 |
Why?
|
| Genetic Therapy | 3 | 2011 | 711 | 0.240 |
Why?
|
| Genes, Dominant | 2 | 2004 | 242 | 0.240 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2026 | 16 | 0.240 |
Why?
|
| DNA, Neoplasm | 4 | 2020 | 282 | 0.240 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2017 | 429 | 0.240 |
Why?
|
| Mice, Knockout | 15 | 2021 | 3814 | 0.230 |
Why?
|
| Immunotherapy | 3 | 2026 | 759 | 0.230 |
Why?
|
| RNA Polymerase III | 3 | 1995 | 19 | 0.230 |
Why?
|
| Liposomes | 2 | 2019 | 197 | 0.230 |
Why?
|
| Homozygote | 3 | 2009 | 534 | 0.230 |
Why?
|
| cdc25 Phosphatases | 1 | 2005 | 19 | 0.230 |
Why?
|
| Sequence Analysis, DNA | 8 | 2013 | 1692 | 0.230 |
Why?
|
| Cytoskeletal Proteins | 1 | 2006 | 259 | 0.230 |
Why?
|
| Carbon | 1 | 2026 | 100 | 0.220 |
Why?
|
| Adenoviridae | 3 | 2011 | 581 | 0.220 |
Why?
|
| Genetic Variation | 4 | 2018 | 1542 | 0.220 |
Why?
|
| Wnt Signaling Pathway | 3 | 2019 | 208 | 0.220 |
Why?
|
| In Situ Hybridization | 9 | 2015 | 436 | 0.220 |
Why?
|
| Fibroblasts | 6 | 2014 | 852 | 0.220 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2017 | 3407 | 0.220 |
Why?
|
| Ubiquitination | 4 | 2021 | 174 | 0.220 |
Why?
|
| MAP Kinase Signaling System | 4 | 2021 | 302 | 0.210 |
Why?
|
| Gene Deletion | 4 | 2012 | 766 | 0.210 |
Why?
|
| Neoplasm Grading | 4 | 2019 | 272 | 0.210 |
Why?
|
| Energy Metabolism | 3 | 2026 | 802 | 0.210 |
Why?
|
| Aged | 29 | 2025 | 20833 | 0.210 |
Why?
|
| COUP Transcription Factor II | 2 | 2016 | 99 | 0.210 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2015 | 194 | 0.200 |
Why?
|
| Interleukin-1 | 2 | 2003 | 130 | 0.200 |
Why?
|
| Receptors, Notch | 3 | 2016 | 197 | 0.200 |
Why?
|
| Wnt Proteins | 3 | 2013 | 191 | 0.200 |
Why?
|
| Dioxins | 1 | 2023 | 4 | 0.200 |
Why?
|
| Prognosis | 14 | 2022 | 4848 | 0.200 |
Why?
|
| Polychlorinated Dibenzodioxins | 1 | 2023 | 6 | 0.200 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 383 | 0.200 |
Why?
|
| Cell Line | 7 | 2017 | 2554 | 0.200 |
Why?
|
| Antineoplastic Agents | 5 | 2019 | 1802 | 0.200 |
Why?
|
| Neoplasm Staging | 9 | 2012 | 1278 | 0.200 |
Why?
|
| DNA Adducts | 1 | 2023 | 70 | 0.190 |
Why?
|
| Homeostasis | 3 | 2023 | 712 | 0.190 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2021 | 354 | 0.190 |
Why?
|
| Smad Proteins | 1 | 2023 | 43 | 0.190 |
Why?
|
| Genomics | 4 | 2022 | 1618 | 0.190 |
Why?
|
| Microsatellite Repeats | 4 | 2016 | 204 | 0.190 |
Why?
|
| Repressor Proteins | 2 | 2017 | 757 | 0.190 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2026 | 282 | 0.190 |
Why?
|
| Gene Silencing | 5 | 2016 | 230 | 0.190 |
Why?
|
| Cholesterol | 1 | 2025 | 537 | 0.180 |
Why?
|
| Kidney Neoplasms | 2 | 2017 | 420 | 0.180 |
Why?
|
| Pancreatic Neoplasms | 4 | 2016 | 735 | 0.180 |
Why?
|
| Creatine Kinase, BB Form | 1 | 2021 | 4 | 0.180 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2009 | 219 | 0.180 |
Why?
|
| Doxycycline | 1 | 2022 | 112 | 0.180 |
Why?
|
| Interleukin-6 | 2 | 2014 | 410 | 0.180 |
Why?
|
| Female | 38 | 2026 | 70285 | 0.180 |
Why?
|
| Papillomaviridae | 2 | 2020 | 179 | 0.180 |
Why?
|
| AMP-Activated Protein Kinases | 3 | 2025 | 168 | 0.180 |
Why?
|
| Nuclear Receptor Coactivator 3 | 6 | 2017 | 257 | 0.170 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2021 | 27 | 0.170 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 2 | 2019 | 43 | 0.170 |
Why?
|
| Autophagy-Related Protein-1 Homolog | 1 | 2021 | 10 | 0.170 |
Why?
|
| Molecular Sequence Data | 12 | 2016 | 3463 | 0.170 |
Why?
|
| Tissue Kallikreins | 1 | 2020 | 7 | 0.170 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 1998 | 75 | 0.170 |
Why?
|
| Cell Adhesion | 3 | 2013 | 308 | 0.170 |
Why?
|
| Fibroblast Growth Factor 7 | 4 | 2003 | 8 | 0.170 |
Why?
|
| Protective Agents | 1 | 2021 | 34 | 0.170 |
Why?
|
| HEK293 Cells | 3 | 2021 | 802 | 0.160 |
Why?
|
| DEAD-box RNA Helicases | 2 | 2013 | 160 | 0.160 |
Why?
|
| Random Allocation | 2 | 2019 | 409 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2017 | 1606 | 0.160 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2021 | 93 | 0.160 |
Why?
|
| Forkhead Transcription Factors | 3 | 2022 | 373 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 13 | 2 | 1997 | 48 | 0.160 |
Why?
|
| Receptor Activator of Nuclear Factor-kappa B | 2 | 2022 | 16 | 0.160 |
Why?
|
| RNA Helicases | 1 | 2021 | 74 | 0.160 |
Why?
|
| Nuclear Receptor Coactivator 2 | 2 | 2015 | 147 | 0.160 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2021 | 584 | 0.160 |
Why?
|
| B7-H1 Antigen | 1 | 2021 | 133 | 0.160 |
Why?
|
| Transcription Factor AP-1 | 3 | 2011 | 110 | 0.160 |
Why?
|
| Pseudogenes | 1 | 2000 | 50 | 0.160 |
Why?
|
| DNA, Mitochondrial | 2 | 2016 | 231 | 0.160 |
Why?
|
| Phenotype | 7 | 2023 | 4464 | 0.160 |
Why?
|
| Breast Neoplasms | 8 | 2017 | 2601 | 0.160 |
Why?
|
| Fibroblast Growth Factor 10 | 4 | 2000 | 21 | 0.160 |
Why?
|
| Inflammation | 5 | 2016 | 1481 | 0.160 |
Why?
|
| Tumor Escape | 1 | 2020 | 62 | 0.150 |
Why?
|
| CD8 Antigens | 1 | 2020 | 39 | 0.150 |
Why?
|
| Inactivation, Metabolic | 1 | 2019 | 25 | 0.150 |
Why?
|
| Time Factors | 10 | 2016 | 6178 | 0.150 |
Why?
|
| Endometrium | 1 | 2023 | 292 | 0.150 |
Why?
|
| Histone Acetyltransferases | 4 | 2008 | 226 | 0.150 |
Why?
|
| Models, Biological | 3 | 2016 | 1376 | 0.150 |
Why?
|
| Base Sequence | 11 | 2016 | 2729 | 0.150 |
Why?
|
| Genes, Retinoblastoma | 2 | 1997 | 22 | 0.150 |
Why?
|
| Cluster Analysis | 4 | 2017 | 412 | 0.150 |
Why?
|
| Autocrine Communication | 1 | 1999 | 29 | 0.150 |
Why?
|
| Neurogenesis | 2 | 2013 | 210 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2019 | 18 | 0.150 |
Why?
|
| Salivary Glands | 1 | 2019 | 35 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 1 | 2019 | 13 | 0.150 |
Why?
|
| Transplantation, Heterologous | 5 | 2013 | 254 | 0.150 |
Why?
|
| Wnt-5a Protein | 1 | 2019 | 23 | 0.150 |
Why?
|
| STAT3 Transcription Factor | 2 | 2017 | 228 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-ets | 2 | 2017 | 58 | 0.150 |
Why?
|
| Databases, Nucleic Acid | 1 | 2019 | 70 | 0.140 |
Why?
|
| Uterus | 1 | 2023 | 545 | 0.140 |
Why?
|
| Pyruvic Acid | 1 | 2018 | 35 | 0.140 |
Why?
|
| TNF Receptor-Associated Factor 4 | 1 | 2018 | 13 | 0.140 |
Why?
|
| Neoplasms, Experimental | 4 | 2016 | 200 | 0.140 |
Why?
|
| Melanoma | 2 | 2013 | 927 | 0.140 |
Why?
|
| Toxicity Tests | 1 | 2018 | 34 | 0.140 |
Why?
|
| Extracellular Matrix | 2 | 2016 | 232 | 0.140 |
Why?
|
| Mammary Neoplasms, Animal | 2 | 2017 | 135 | 0.140 |
Why?
|
| Relaxin | 2 | 2009 | 16 | 0.140 |
Why?
|
| Receptor, trkA | 1 | 2018 | 18 | 0.140 |
Why?
|
| RNA, Long Noncoding | 1 | 2021 | 219 | 0.140 |
Why?
|
| Proteomics | 2 | 2025 | 615 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2016 | 720 | 0.140 |
Why?
|
| Neoplasms, Hormone-Dependent | 3 | 2007 | 87 | 0.140 |
Why?
|
| Camptothecin | 1 | 2018 | 76 | 0.140 |
Why?
|
| Multigene Family | 2 | 2017 | 289 | 0.130 |
Why?
|
| Healthcare Disparities | 2 | 2022 | 514 | 0.130 |
Why?
|
| Proteoglycans | 3 | 2015 | 78 | 0.130 |
Why?
|
| Denervation | 1 | 2017 | 24 | 0.130 |
Why?
|
| Blotting, Southern | 4 | 2000 | 203 | 0.130 |
Why?
|
| Neuroendocrine Tumors | 1 | 2018 | 67 | 0.130 |
Why?
|
| Polymorphism, Genetic | 4 | 2008 | 776 | 0.130 |
Why?
|
| Caveolins | 3 | 2002 | 14 | 0.130 |
Why?
|
| Genetic Engineering | 3 | 2016 | 161 | 0.130 |
Why?
|
| Aged, 80 and over | 12 | 2020 | 6768 | 0.130 |
Why?
|
| Retroviridae | 2 | 2017 | 182 | 0.130 |
Why?
|
| Ureteral Neoplasms | 1 | 2017 | 19 | 0.130 |
Why?
|
| Ligands | 3 | 2022 | 481 | 0.130 |
Why?
|
| DNA Damage | 2 | 2023 | 509 | 0.130 |
Why?
|
| Urologic Neoplasms | 1 | 2017 | 30 | 0.130 |
Why?
|
| Metabolic Syndrome | 1 | 2021 | 365 | 0.130 |
Why?
|
| RNAi Therapeutics | 1 | 2017 | 17 | 0.130 |
Why?
|
| Insulin Resistance | 1 | 2022 | 685 | 0.130 |
Why?
|
| T-Lymphocytes | 3 | 2015 | 1710 | 0.130 |
Why?
|
| Kidney Pelvis | 1 | 2017 | 33 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2024 | 2824 | 0.130 |
Why?
|
| Urothelium | 1 | 2017 | 55 | 0.130 |
Why?
|
| Chromosome Aberrations | 2 | 2016 | 573 | 0.130 |
Why?
|
| CELF1 Protein | 1 | 2016 | 34 | 0.120 |
Why?
|
| GATA Transcription Factors | 1 | 2016 | 7 | 0.120 |
Why?
|
| G-Protein-Coupled Receptor Kinase 3 | 1 | 2016 | 9 | 0.120 |
Why?
|
| Genome, Human | 2 | 2015 | 1315 | 0.120 |
Why?
|
| Survival Analysis | 4 | 2017 | 1481 | 0.120 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2016 | 31 | 0.120 |
Why?
|
| Collagen Type I | 1 | 2016 | 110 | 0.120 |
Why?
|
| Forkhead Box Protein M1 | 1 | 2016 | 8 | 0.120 |
Why?
|
| Hexosamines | 1 | 2016 | 17 | 0.120 |
Why?
|
| Nanoparticles | 1 | 2019 | 298 | 0.120 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 903 | 0.120 |
Why?
|
| Models, Animal | 1 | 2018 | 450 | 0.120 |
Why?
|
| Jagged-1 Protein | 1 | 2016 | 51 | 0.120 |
Why?
|
| Receptors, Calcitriol | 2 | 2014 | 60 | 0.120 |
Why?
|
| Comparative Genomic Hybridization | 3 | 2016 | 567 | 0.120 |
Why?
|
| Ureter | 1 | 2017 | 84 | 0.120 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2016 | 132 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1215 | 0.120 |
Why?
|
| DNA Copy Number Variations | 2 | 2011 | 1026 | 0.120 |
Why?
|
| Nuclear Receptor Co-Repressor 1 | 1 | 2016 | 52 | 0.120 |
Why?
|
| Cell Transdifferentiation | 1 | 2016 | 58 | 0.120 |
Why?
|
| Duodenal Neoplasms | 1 | 2016 | 27 | 0.120 |
Why?
|
| NADPH Oxidase 4 | 1 | 2015 | 13 | 0.120 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 5 | 2003 | 37 | 0.120 |
Why?
|
| Receptor, Notch1 | 1 | 2016 | 78 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2015 | 27 | 0.120 |
Why?
|
| Semaphorins | 2 | 2013 | 40 | 0.120 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2017 | 127 | 0.120 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2016 | 73 | 0.120 |
Why?
|
| Interphase | 2 | 1993 | 37 | 0.120 |
Why?
|
| Chromosomes, Human | 1 | 2016 | 118 | 0.120 |
Why?
|
| Rats | 6 | 2023 | 3378 | 0.110 |
Why?
|
| Receptors, Estrogen | 1 | 2019 | 731 | 0.110 |
Why?
|
| Gene Targeting | 1 | 2016 | 169 | 0.110 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 1997 | 218 | 0.110 |
Why?
|
| Ribonuclease III | 2 | 2013 | 100 | 0.110 |
Why?
|
| Microfilament Proteins | 2 | 2016 | 269 | 0.110 |
Why?
|
| NADPH Oxidases | 1 | 2015 | 109 | 0.110 |
Why?
|
| Transcription Factor RelA | 1 | 2015 | 49 | 0.110 |
Why?
|
| Carcinoma, Papillary | 1 | 2015 | 91 | 0.110 |
Why?
|
| Papillomavirus Infections | 1 | 2019 | 390 | 0.110 |
Why?
|
| Germ Cells | 1 | 2016 | 201 | 0.110 |
Why?
|
| Statistics as Topic | 1 | 2015 | 242 | 0.110 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2014 | 18 | 0.110 |
Why?
|
| In Vitro Techniques | 3 | 2012 | 806 | 0.110 |
Why?
|
| Benzylamines | 1 | 2014 | 22 | 0.110 |
Why?
|
| GATA2 Transcription Factor | 1 | 2014 | 46 | 0.110 |
Why?
|
| Neurons | 3 | 2016 | 1979 | 0.110 |
Why?
|
| Cell Adhesion Molecules | 2 | 2025 | 222 | 0.110 |
Why?
|
| Acetyltransferases | 2 | 2023 | 74 | 0.110 |
Why?
|
| Benzoates | 1 | 2014 | 24 | 0.110 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2015 | 137 | 0.110 |
Why?
|
| Exons | 5 | 2008 | 759 | 0.110 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2016 | 209 | 0.110 |
Why?
|
| Steroid Hydroxylases | 1 | 2014 | 19 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1996 | 363 | 0.100 |
Why?
|
| Nuclear Receptor Coactivators | 1 | 2014 | 64 | 0.100 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2014 | 104 | 0.100 |
Why?
|
| Cathepsin D | 1 | 2014 | 16 | 0.100 |
Why?
|
| Case-Control Studies | 5 | 2019 | 3350 | 0.100 |
Why?
|
| Neoplasms, Basal Cell | 1 | 2013 | 8 | 0.100 |
Why?
|
| Antigens, CD34 | 1 | 2014 | 97 | 0.100 |
Why?
|
| Phosphorylcholine | 2 | 2011 | 31 | 0.100 |
Why?
|
| Chromosome Mapping | 6 | 2006 | 1045 | 0.100 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2013 | 30 | 0.100 |
Why?
|
| Neuroepithelial Cells | 1 | 2013 | 9 | 0.100 |
Why?
|
| Isoenzymes | 2 | 2005 | 212 | 0.100 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2014 | 68 | 0.100 |
Why?
|
| Interleukin-4 | 1 | 2014 | 145 | 0.100 |
Why?
|
| Survival Rate | 4 | 2021 | 2112 | 0.100 |
Why?
|
| Recurrence | 4 | 2016 | 1476 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2013 | 61 | 0.100 |
Why?
|
| Prostatitis | 1 | 2013 | 22 | 0.100 |
Why?
|
| Mannosidases | 1 | 2013 | 17 | 0.100 |
Why?
|
| Drug Delivery Systems | 2 | 2026 | 217 | 0.100 |
Why?
|
| Chordoma | 1 | 2013 | 18 | 0.100 |
Why?
|
| Neuroblastoma | 2 | 2016 | 547 | 0.100 |
Why?
|
| Mediator Complex Subunit 1 | 1 | 2013 | 2 | 0.100 |
Why?
|
| Testosterone | 4 | 2011 | 528 | 0.100 |
Why?
|
| New York | 1 | 2013 | 69 | 0.100 |
Why?
|
| Sulfotransferases | 1 | 2013 | 28 | 0.100 |
Why?
|
| HSC70 Heat-Shock Proteins | 1 | 2012 | 4 | 0.100 |
Why?
|
| Flow Cytometry | 4 | 2015 | 766 | 0.100 |
Why?
|
| Skull Base Neoplasms | 1 | 2013 | 39 | 0.100 |
Why?
|
| Biopsy | 4 | 2024 | 1237 | 0.100 |
Why?
|
| Chromosome Deletion | 1 | 1996 | 654 | 0.100 |
Why?
|
| Lipoproteins, VLDL | 2 | 1983 | 53 | 0.100 |
Why?
|
| CDC2 Protein Kinase | 2 | 2004 | 36 | 0.100 |
Why?
|
| Nitriles | 4 | 2016 | 161 | 0.090 |
Why?
|
| Genotype | 5 | 2016 | 2588 | 0.090 |
Why?
|
| Aurora Kinase A | 1 | 2012 | 36 | 0.090 |
Why?
|
| Microbiological Techniques | 1 | 2012 | 33 | 0.090 |
Why?
|
| Mouth Diseases | 1 | 1992 | 16 | 0.090 |
Why?
|
| Adoptive Transfer | 1 | 2013 | 235 | 0.090 |
Why?
|
| Urine | 1 | 2012 | 89 | 0.090 |
Why?
|
| Glutathione S-Transferase pi | 2 | 2010 | 25 | 0.090 |
Why?
|
| Caveolin 1 | 4 | 2006 | 51 | 0.090 |
Why?
|
| Oxidative Stress | 2 | 2015 | 793 | 0.090 |
Why?
|
| Vitamin D | 1 | 2014 | 192 | 0.090 |
Why?
|
| Loss of Heterozygosity | 4 | 2004 | 123 | 0.090 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2010 | 142 | 0.090 |
Why?
|
| Macrophages | 1 | 2016 | 660 | 0.090 |
Why?
|
| Vasculitis | 1 | 1992 | 47 | 0.090 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-5 | 1 | 2012 | 9 | 0.090 |
Why?
|
| Biopsy, Needle | 2 | 2006 | 204 | 0.090 |
Why?
|
| Peripheral Nerves | 3 | 2008 | 89 | 0.090 |
Why?
|
| Receptors, Peptide | 2 | 2009 | 54 | 0.090 |
Why?
|
| Genes, Suppressor | 1 | 2011 | 11 | 0.090 |
Why?
|
| Macaca mulatta | 2 | 2023 | 492 | 0.090 |
Why?
|
| Orchiectomy | 5 | 2013 | 46 | 0.090 |
Why?
|
| Diet | 1 | 2018 | 1097 | 0.090 |
Why?
|
| Aging | 2 | 2010 | 1236 | 0.090 |
Why?
|
| Cancer Vaccines | 1 | 2013 | 188 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2020 | 891 | 0.090 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2012 | 246 | 0.090 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2015 | 499 | 0.090 |
Why?
|
| Disease-Free Survival | 4 | 2016 | 902 | 0.090 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2011 | 23 | 0.090 |
Why?
|
| Chromosome Breakpoints | 1 | 2011 | 82 | 0.080 |
Why?
|
| Protein Multimerization | 1 | 2012 | 149 | 0.080 |
Why?
|
| Transgenes | 3 | 2007 | 316 | 0.080 |
Why?
|
| Gene Dosage | 2 | 2011 | 435 | 0.080 |
Why?
|
| Arachidonic Acid | 1 | 2011 | 52 | 0.080 |
Why?
|
| Ganglia | 1 | 2010 | 13 | 0.080 |
Why?
|
| Amino Acid Sequence | 8 | 2012 | 2390 | 0.080 |
Why?
|
| Ki-67 Antigen | 3 | 2006 | 100 | 0.080 |
Why?
|
| Osteonectin | 1 | 2010 | 7 | 0.080 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 1 | 2010 | 4 | 0.080 |
Why?
|
| Homeobox Protein Nkx-2.5 | 1 | 2010 | 20 | 0.080 |
Why?
|
| COS Cells | 1 | 2010 | 253 | 0.080 |
Why?
|
| HeLa Cells | 5 | 2015 | 689 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2006 | 690 | 0.080 |
Why?
|
| Antigens, Neoplasm | 1 | 2013 | 393 | 0.080 |
Why?
|
| DNA | 5 | 2006 | 1400 | 0.080 |
Why?
|
| Lymphatic Metastasis | 3 | 2006 | 425 | 0.080 |
Why?
|
| Health | 1 | 2010 | 35 | 0.080 |
Why?
|
| Antibodies | 4 | 2013 | 317 | 0.080 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2010 | 77 | 0.080 |
Why?
|
| Androgen-Binding Protein | 2 | 2007 | 20 | 0.080 |
Why?
|
| Lipid Metabolism | 2 | 2024 | 371 | 0.080 |
Why?
|
| Dihydrotestosterone | 2 | 2007 | 55 | 0.080 |
Why?
|
| Mitogens | 2 | 2000 | 30 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2019 | 3680 | 0.080 |
Why?
|
| Adult | 15 | 2019 | 31042 | 0.080 |
Why?
|
| beta Catenin | 3 | 2019 | 198 | 0.080 |
Why?
|
| Endopeptidases | 1 | 2010 | 106 | 0.080 |
Why?
|
| Peptides | 1 | 2013 | 704 | 0.080 |
Why?
|
| Ganglia, Spinal | 2 | 2006 | 65 | 0.080 |
Why?
|
| Endoribonucleases | 1 | 2010 | 87 | 0.080 |
Why?
|
| Proportional Hazards Models | 4 | 2016 | 1392 | 0.080 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2009 | 10 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2005 | 165 | 0.070 |
Why?
|
| Heterozygote | 3 | 1996 | 722 | 0.070 |
Why?
|
| CDC28 Protein Kinase, S cerevisiae | 1 | 2008 | 2 | 0.070 |
Why?
|
| Databases, Genetic | 3 | 2017 | 500 | 0.070 |
Why?
|
| Protein Binding | 4 | 2018 | 1650 | 0.070 |
Why?
|
| CDC2-CDC28 Kinases | 1 | 2008 | 20 | 0.070 |
Why?
|
| Polyomavirus Infections | 1 | 2009 | 87 | 0.070 |
Why?
|
| Boronic Acids | 1 | 2008 | 48 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2013 | 790 | 0.070 |
Why?
|
| Tumor Virus Infections | 1 | 2009 | 131 | 0.070 |
Why?
|
| Risk | 3 | 2020 | 723 | 0.070 |
Why?
|
| Focal Adhesions | 1 | 2008 | 14 | 0.070 |
Why?
|
| Simian virus 40 | 1 | 2009 | 190 | 0.070 |
Why?
|
| Pyrazines | 1 | 2008 | 79 | 0.070 |
Why?
|
| Cohort Studies | 5 | 2018 | 5042 | 0.070 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2008 | 82 | 0.070 |
Why?
|
| Matrix Metalloproteinases | 1 | 2008 | 62 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 3 | 2013 | 234 | 0.070 |
Why?
|
| Sensitivity and Specificity | 3 | 2012 | 2079 | 0.070 |
Why?
|
| Urinary Tract Infections | 1 | 2012 | 330 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 5 | 2016 | 978 | 0.070 |
Why?
|
| DNA, Complementary | 2 | 2008 | 421 | 0.070 |
Why?
|
| Veterans | 1 | 2019 | 1752 | 0.070 |
Why?
|
| Epigenomics | 2 | 2023 | 181 | 0.070 |
Why?
|
| Azasteroids | 1 | 2007 | 1 | 0.070 |
Why?
|
| Wound Healing | 2 | 2004 | 486 | 0.070 |
Why?
|
| Algorithms | 2 | 2013 | 1661 | 0.070 |
Why?
|
| Epigenesis, Genetic | 3 | 2019 | 761 | 0.070 |
Why?
|
| Microspheres | 1 | 2007 | 66 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2023 | 354 | 0.070 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2007 | 43 | 0.070 |
Why?
|
| Sequence Deletion | 3 | 2017 | 517 | 0.070 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2007 | 9 | 0.070 |
Why?
|
| Mesoderm | 1 | 2007 | 104 | 0.070 |
Why?
|
| Receptors, Neuropeptide | 1 | 2007 | 13 | 0.070 |
Why?
|
| Cartilage | 1 | 2007 | 52 | 0.060 |
Why?
|
| Cell Death | 2 | 2012 | 227 | 0.060 |
Why?
|
| Genomic Instability | 2 | 2021 | 245 | 0.060 |
Why?
|
| Recombinant Proteins | 2 | 2000 | 1317 | 0.060 |
Why?
|
| Metribolone | 3 | 2013 | 28 | 0.060 |
Why?
|
| Adipocytes, Brown | 1 | 2007 | 27 | 0.060 |
Why?
|
| Chondrogenesis | 1 | 2007 | 30 | 0.060 |
Why?
|
| Somatomedins | 1 | 2006 | 33 | 0.060 |
Why?
|
| Liver | 3 | 2002 | 1788 | 0.060 |
Why?
|
| Chondrocytes | 1 | 2007 | 48 | 0.060 |
Why?
|
| Prostatic Diseases | 1 | 2006 | 12 | 0.060 |
Why?
|
| Ossification, Heterotopic | 1 | 2007 | 36 | 0.060 |
Why?
|
| Smad4 Protein | 2 | 2020 | 57 | 0.060 |
Why?
|
| Neurites | 1 | 2006 | 43 | 0.060 |
Why?
|
| Cell Line, Transformed | 1 | 2006 | 159 | 0.060 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2009 | 289 | 0.060 |
Why?
|
| Herpesvirus 4, Human | 1 | 2009 | 639 | 0.060 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2003 | 82 | 0.060 |
Why?
|
| Gene Rearrangement | 2 | 2020 | 322 | 0.060 |
Why?
|
| Polyglycolic Acid | 1 | 2026 | 23 | 0.060 |
Why?
|
| Drug Liberation | 1 | 2026 | 44 | 0.060 |
Why?
|
| Estrenes | 1 | 2006 | 15 | 0.060 |
Why?
|
| Osteogenesis | 1 | 2007 | 180 | 0.060 |
Why?
|
| Polyesters | 1 | 2026 | 37 | 0.060 |
Why?
|
| Enzyme Activation | 4 | 2009 | 576 | 0.060 |
Why?
|
| Lymphoma | 1 | 2009 | 327 | 0.060 |
Why?
|
| Delayed-Action Preparations | 1 | 2026 | 121 | 0.060 |
Why?
|
| F-Box Proteins | 1 | 2006 | 32 | 0.060 |
Why?
|
| Models, Genetic | 1 | 2009 | 748 | 0.060 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 2 | 2016 | 44 | 0.060 |
Why?
|
| Muscle, Skeletal | 3 | 2007 | 979 | 0.060 |
Why?
|
| Genetic Vectors | 3 | 2011 | 893 | 0.060 |
Why?
|
| Glutamine | 2 | 2018 | 201 | 0.060 |
Why?
|
| Phenylthiohydantoin | 2 | 2016 | 15 | 0.060 |
Why?
|
| Lactic Acid | 1 | 2026 | 146 | 0.060 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 2 | 2018 | 196 | 0.060 |
Why?
|
| Monocytes | 1 | 2007 | 335 | 0.060 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2013 | 86 | 0.060 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 1 | 2025 | 82 | 0.060 |
Why?
|
| Plasmids | 3 | 2004 | 446 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 2289 | 0.060 |
Why?
|
| Base Pair Mismatch | 1 | 2004 | 19 | 0.050 |
Why?
|
| Oncogene Proteins | 1 | 2005 | 136 | 0.050 |
Why?
|
| Seminal Vesicles | 3 | 2013 | 51 | 0.050 |
Why?
|
| Immunity | 2 | 2022 | 179 | 0.050 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2004 | 22 | 0.050 |
Why?
|
| Coculture Techniques | 3 | 2013 | 230 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 559 | 0.050 |
Why?
|
| RNA | 3 | 2011 | 511 | 0.050 |
Why?
|
| Chromosomal Instability | 1 | 2004 | 59 | 0.050 |
Why?
|
| Hep G2 Cells | 2 | 2015 | 84 | 0.050 |
Why?
|
| Laminin | 1 | 2004 | 66 | 0.050 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2013 | 977 | 0.050 |
Why?
|
| Azacitidine | 2 | 2015 | 51 | 0.050 |
Why?
|
| Biomarkers | 1 | 2014 | 3360 | 0.050 |
Why?
|
| G2 Phase | 1 | 2004 | 39 | 0.050 |
Why?
|
| Deoxyadenosines | 1 | 2023 | 11 | 0.050 |
Why?
|
| Antigens | 1 | 2004 | 104 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2004 | 82 | 0.050 |
Why?
|
| Microarray Analysis | 2 | 2014 | 223 | 0.050 |
Why?
|
| Oxygen | 1 | 2007 | 549 | 0.050 |
Why?
|
| MCF-7 Cells | 2 | 2015 | 208 | 0.050 |
Why?
|
| Testis | 1 | 2006 | 389 | 0.050 |
Why?
|
| Fibroblast Growth Factor 1 | 1 | 2003 | 13 | 0.050 |
Why?
|
| Lipolysis | 1 | 2024 | 77 | 0.050 |
Why?
|
| Sialoglycoproteins | 1 | 2003 | 43 | 0.050 |
Why?
|
| Culture Media, Conditioned | 2 | 2001 | 83 | 0.050 |
Why?
|
| Lipase | 1 | 2024 | 88 | 0.050 |
Why?
|
| Macaca | 1 | 2023 | 60 | 0.050 |
Why?
|
| Cyclins | 1 | 2004 | 93 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2004 | 268 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 2 | 2017 | 409 | 0.050 |
Why?
|
| Cell Growth Processes | 3 | 2011 | 62 | 0.050 |
Why?
|
| Polychlorinated Biphenyls | 1 | 2023 | 14 | 0.050 |
Why?
|
| Glycine | 1 | 2004 | 156 | 0.050 |
Why?
|
| Testicular Neoplasms | 1 | 2004 | 112 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2004 | 226 | 0.050 |
Why?
|
| Reproducibility of Results | 4 | 2013 | 2896 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2003 | 88 | 0.050 |
Why?
|
| Serine | 1 | 2024 | 161 | 0.050 |
Why?
|
| Tenofovir | 1 | 2023 | 26 | 0.050 |
Why?
|
| Collagen | 1 | 2004 | 274 | 0.050 |
Why?
|
| Animals, Genetically Modified | 1 | 2004 | 291 | 0.050 |
Why?
|
| DNA Primers | 3 | 2010 | 600 | 0.050 |
Why?
|
| Cell Culture Techniques | 1 | 2004 | 273 | 0.050 |
Why?
|
| beta-Galactosidase | 1 | 2003 | 135 | 0.050 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2003 | 112 | 0.050 |
Why?
|
| Gene Transfer Techniques | 2 | 2017 | 344 | 0.050 |
Why?
|
| Agglutinins | 1 | 2022 | 7 | 0.050 |
Why?
|
| Keratin-5 | 1 | 2022 | 9 | 0.050 |
Why?
|
| Species Specificity | 2 | 2013 | 472 | 0.050 |
Why?
|
| Precancerous Conditions | 3 | 2015 | 281 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2013 | 1368 | 0.050 |
Why?
|
| Immunization | 1 | 2004 | 268 | 0.050 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2015 | 186 | 0.050 |
Why?
|
| Proteasome Inhibitors | 2 | 2017 | 53 | 0.050 |
Why?
|
| Glutathione Transferase | 1 | 2003 | 147 | 0.050 |
Why?
|
| Alanine | 1 | 2023 | 159 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 1070 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2004 | 420 | 0.050 |
Why?
|
| Genetic Complementation Test | 3 | 1993 | 89 | 0.050 |
Why?
|
| Thymus Gland | 1 | 2022 | 105 | 0.050 |
Why?
|
| Adenine | 1 | 2023 | 119 | 0.050 |
Why?
|
| Mutagenesis | 1 | 2023 | 325 | 0.050 |
Why?
|
| Anti-Retroviral Agents | 1 | 2023 | 154 | 0.050 |
Why?
|
| Endocytosis | 1 | 1982 | 121 | 0.050 |
Why?
|
| Cytogenetics | 1 | 2001 | 13 | 0.040 |
Why?
|
| Cyclin B1 | 1 | 2001 | 7 | 0.040 |
Why?
|
| Texas | 3 | 2017 | 3648 | 0.040 |
Why?
|
| Precipitin Tests | 1 | 2001 | 109 | 0.040 |
Why?
|
| Arginine | 1 | 2004 | 336 | 0.040 |
Why?
|
| Cricetinae | 3 | 1993 | 361 | 0.040 |
Why?
|
| Cyclin B | 1 | 2001 | 22 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2006 | 622 | 0.040 |
Why?
|
| Lac Operon | 1 | 2001 | 88 | 0.040 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2001 | 40 | 0.040 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2021 | 61 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2003 | 331 | 0.040 |
Why?
|
| Chromosomes | 1 | 2001 | 120 | 0.040 |
Why?
|
| 3T3 Cells | 2 | 2007 | 117 | 0.040 |
Why?
|
| Progesterone | 1 | 2003 | 440 | 0.040 |
Why?
|
| Estradiol | 1 | 2003 | 461 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2021 | 131 | 0.040 |
Why?
|
| Fasting | 1 | 1982 | 304 | 0.040 |
Why?
|
| BRCA2 Protein | 2 | 1999 | 56 | 0.040 |
Why?
|
| Chloroquine | 1 | 2021 | 30 | 0.040 |
Why?
|
| Carcinogens | 1 | 2021 | 128 | 0.040 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2002 | 235 | 0.040 |
Why?
|
| Dependovirus | 1 | 2002 | 159 | 0.040 |
Why?
|
| Sequence Alignment | 2 | 2011 | 583 | 0.040 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2001 | 26 | 0.040 |
Why?
|
| Carcinoma, Giant Cell | 1 | 2020 | 1 | 0.040 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2020 | 5 | 0.040 |
Why?
|
| Enzyme Induction | 2 | 2013 | 92 | 0.040 |
Why?
|
| Fibroblast Growth Factor 6 | 1 | 2000 | 3 | 0.040 |
Why?
|
| Protein Transport | 2 | 2012 | 364 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2023 | 1110 | 0.040 |
Why?
|
| Binding Sites | 3 | 2011 | 1135 | 0.040 |
Why?
|
| Cloning, Molecular | 4 | 1993 | 778 | 0.040 |
Why?
|
| Glucuronic Acid | 1 | 2019 | 13 | 0.040 |
Why?
|
| S-Adenosylhomocysteine | 1 | 2019 | 15 | 0.040 |
Why?
|
| S-Adenosylmethionine | 1 | 2019 | 26 | 0.040 |
Why?
|
| Reference Values | 1 | 2001 | 674 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2024 | 416 | 0.040 |
Why?
|
| Fibroblast Growth Factor 9 | 1 | 1999 | 9 | 0.040 |
Why?
|
| MAP Kinase Kinase 7 | 1 | 2019 | 12 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2022 | 17554 | 0.040 |
Why?
|
| Chromatography, Affinity | 1 | 1999 | 52 | 0.040 |
Why?
|
| Jews | 1 | 1999 | 33 | 0.040 |
Why?
|
| Viral Vaccines | 1 | 2002 | 322 | 0.040 |
Why?
|
| Bradykinin | 1 | 1999 | 42 | 0.040 |
Why?
|
| Genes, BRCA1 | 1 | 1999 | 58 | 0.040 |
Why?
|
| Computational Biology | 2 | 2017 | 862 | 0.040 |
Why?
|
| Receptor Cross-Talk | 1 | 2019 | 36 | 0.040 |
Why?
|
| Thrombospondin 1 | 1 | 1999 | 23 | 0.040 |
Why?
|
| Diet, High-Fat | 1 | 2021 | 268 | 0.040 |
Why?
|
| Stem Cell Niche | 1 | 2019 | 54 | 0.040 |
Why?
|
| ROC Curve | 2 | 2014 | 609 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2020 | 742 | 0.040 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 1999 | 98 | 0.040 |
Why?
|
| Carboxylesterase | 1 | 2018 | 6 | 0.040 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2018 | 38 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2019 | 232 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 216 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2022 | 278 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2022 | 902 | 0.030 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2018 | 59 | 0.030 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2018 | 69 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2020 | 223 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2006 | 411 | 0.030 |
Why?
|
| Luciferases | 2 | 2011 | 126 | 0.030 |
Why?
|
| Biological Transport | 1 | 2018 | 328 | 0.030 |
Why?
|
| Endothelin-1 | 1 | 1998 | 40 | 0.030 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 1998 | 23 | 0.030 |
Why?
|
| Inhibitor of Differentiation Protein 1 | 1 | 2017 | 3 | 0.030 |
Why?
|
| Atrophy | 2 | 2010 | 246 | 0.030 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 1998 | 37 | 0.030 |
Why?
|
| Acetylcholine Release Inhibitors | 1 | 2017 | 18 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 2 | 2011 | 402 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2018 | 192 | 0.030 |
Why?
|
| Parvovirus B19, Human | 1 | 1997 | 27 | 0.030 |
Why?
|
| Autophagy | 1 | 2021 | 419 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2018 | 85 | 0.030 |
Why?
|
| Parvoviridae Infections | 1 | 1997 | 35 | 0.030 |
Why?
|
| Glycogen Synthase Kinases | 1 | 2017 | 6 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligase Complexes | 1 | 2017 | 25 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2019 | 286 | 0.030 |
Why?
|
| Sequence Analysis, Protein | 1 | 2017 | 48 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2017 | 68 | 0.030 |
Why?
|
| Second Harmonic Generation Microscopy | 1 | 2016 | 5 | 0.030 |
Why?
|
| Prealbumin | 1 | 1997 | 27 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 1999 | 372 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2017 | 57 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 2 | 2013 | 306 | 0.030 |
Why?
|
| AC133 Antigen | 1 | 2016 | 34 | 0.030 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2017 | 99 | 0.030 |
Why?
|
| Vaccination | 1 | 2002 | 1056 | 0.030 |
Why?
|
| Interleukin-1alpha | 1 | 2016 | 11 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2010 | 929 | 0.030 |
Why?
|
| Leukocyte Common Antigens | 1 | 2016 | 84 | 0.030 |
Why?
|
| Chemokine CXCL10 | 1 | 2016 | 52 | 0.030 |
Why?
|
| Neutrophil Infiltration | 1 | 2016 | 63 | 0.030 |
Why?
|
| Organ Size | 2 | 2010 | 408 | 0.030 |
Why?
|
| Tosyl Compounds | 1 | 2016 | 22 | 0.030 |
Why?
|
| Protein Array Analysis | 1 | 2016 | 104 | 0.030 |
Why?
|
| DNA Probes | 1 | 1996 | 117 | 0.030 |
Why?
|
| Mice, Inbred ICR | 2 | 2013 | 137 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2016 | 112 | 0.030 |
Why?
|
| Diarrhea | 1 | 2018 | 315 | 0.030 |
Why?
|
| Ampulla of Vater | 1 | 2016 | 15 | 0.030 |
Why?
|
| United States | 2 | 2024 | 11885 | 0.030 |
Why?
|
| Fatty Liver | 1 | 2018 | 218 | 0.030 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2016 | 25 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2016 | 156 | 0.030 |
Why?
|
| Amyloidosis | 1 | 1997 | 70 | 0.030 |
Why?
|
| Anilides | 1 | 2016 | 52 | 0.030 |
Why?
|
| Mesocricetus | 2 | 1993 | 65 | 0.030 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2015 | 41 | 0.030 |
Why?
|
| Bone Morphogenetic Proteins | 2 | 2007 | 127 | 0.030 |
Why?
|
| Metabolomics | 1 | 2019 | 501 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2015 | 59 | 0.030 |
Why?
|
| Metabolome | 1 | 2018 | 325 | 0.030 |
Why?
|
| Bone Marrow | 1 | 1997 | 318 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 5161 | 0.030 |
Why?
|
| G1 Phase | 1 | 2015 | 68 | 0.030 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 60 | 0.030 |
Why?
|
| Introns | 3 | 2006 | 279 | 0.030 |
Why?
|
| Bone Morphogenetic Protein 6 | 1 | 2014 | 8 | 0.030 |
Why?
|
| Pteridines | 1 | 2014 | 10 | 0.030 |
Why?
|
| Kallikreins | 1 | 2014 | 26 | 0.030 |
Why?
|
| RNA, Ribosomal | 1 | 1995 | 48 | 0.030 |
Why?
|
| Liver X Receptors | 1 | 2014 | 14 | 0.030 |
Why?
|
| Anoikis | 1 | 2014 | 8 | 0.030 |
Why?
|
| Blood Physiological Phenomena | 1 | 1994 | 5 | 0.030 |
Why?
|
| Cycloheximide | 1 | 1994 | 40 | 0.030 |
Why?
|
| Lipogenesis | 1 | 2015 | 61 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2012 | 613 | 0.030 |
Why?
|
| Vitamin D3 24-Hydroxylase | 1 | 2014 | 11 | 0.030 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2014 | 38 | 0.030 |
Why?
|
| Cell Separation | 1 | 2015 | 220 | 0.030 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2015 | 88 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2015 | 395 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2014 | 81 | 0.030 |
Why?
|
| DNA, Single-Stranded | 1 | 1994 | 69 | 0.030 |
Why?
|
| Keratin-14 | 1 | 2013 | 10 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 374 | 0.030 |
Why?
|
| Body Weight | 1 | 2018 | 985 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 1994 | 79 | 0.030 |
Why?
|
| Cellular Microenvironment | 1 | 2013 | 12 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2015 | 277 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2015 | 434 | 0.030 |
Why?
|
| Receptors, Antigen | 1 | 2013 | 33 | 0.030 |
Why?
|
| Gene Amplification | 1 | 1994 | 219 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 2016 | 571 | 0.030 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2014 | 110 | 0.030 |
Why?
|
| Heparin | 1 | 2015 | 204 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 303 | 0.030 |
Why?
|
| Keratins | 2 | 2004 | 49 | 0.030 |
Why?
|
| Thymidine | 2 | 2006 | 49 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2013 | 130 | 0.020 |
Why?
|
| DNA Footprinting | 1 | 2013 | 12 | 0.020 |
Why?
|
| Genes, Fungal | 1 | 1993 | 57 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2013 | 189 | 0.020 |
Why?
|
| Cell Dedifferentiation | 1 | 2013 | 20 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2017 | 12843 | 0.020 |
Why?
|
| Fibrosarcoma | 1 | 1993 | 21 | 0.020 |
Why?
|
| Cryptococcosis | 1 | 1993 | 38 | 0.020 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2014 | 265 | 0.020 |
Why?
|
| Subcellular Fractions | 2 | 2003 | 89 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 2012 | 9 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2013 | 71 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning Transmission | 1 | 2012 | 5 | 0.020 |
Why?
|
| Calcitriol | 1 | 2013 | 63 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2013 | 300 | 0.020 |
Why?
|
| Oxidative Phosphorylation | 1 | 2013 | 141 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 526 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2013 | 164 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2013 | 271 | 0.020 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2012 | 16 | 0.020 |
Why?
|
| Response Elements | 1 | 2013 | 102 | 0.020 |
Why?
|
| Glycolysis | 1 | 2013 | 174 | 0.020 |
Why?
|
| Starvation | 2 | 1983 | 17 | 0.020 |
Why?
|
| Yeasts | 1 | 2012 | 43 | 0.020 |
Why?
|
| Bacterial Load | 1 | 2012 | 34 | 0.020 |
Why?
|
| Tongue Diseases | 1 | 1992 | 11 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2012 | 86 | 0.020 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2012 | 59 | 0.020 |
Why?
|
| Leg Ulcer | 1 | 1992 | 12 | 0.020 |
Why?
|
| Nitrites | 1 | 2012 | 48 | 0.020 |
Why?
|
| Fungal Proteins | 1 | 1993 | 136 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2013 | 109 | 0.020 |
Why?
|
| Protein Interaction Maps | 1 | 2012 | 93 | 0.020 |
Why?
|
| Temperature | 1 | 1993 | 288 | 0.020 |
Why?
|
| Ulcer | 1 | 1992 | 50 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 1992 | 45 | 0.020 |
Why?
|
| Mesothelioma | 1 | 2013 | 96 | 0.020 |
Why?
|
| Casein Kinase I | 1 | 2012 | 11 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2012 | 246 | 0.020 |
Why?
|
| Axin Protein | 1 | 2012 | 18 | 0.020 |
Why?
|
| Estradiol Dehydrogenases | 1 | 2011 | 3 | 0.020 |
Why?
|
| Necrosis | 1 | 1992 | 193 | 0.020 |
Why?
|
| Dishevelled Proteins | 1 | 2012 | 40 | 0.020 |
Why?
|
| Intracellular Space | 1 | 2012 | 46 | 0.020 |
Why?
|
| Casein Kinase Ialpha | 1 | 2011 | 4 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 1872 | 0.020 |
Why?
|
| HLA Antigens | 1 | 2013 | 225 | 0.020 |
Why?
|
| Cardiomyopathies | 1 | 1997 | 519 | 0.020 |
Why?
|
| Retinoblastoma Protein | 1 | 2011 | 78 | 0.020 |
Why?
|
| Glioblastoma | 2 | 2011 | 372 | 0.020 |
Why?
|
| Membrane Microdomains | 1 | 2012 | 60 | 0.020 |
Why?
|
| Autopsy | 1 | 2011 | 113 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 12 | 1 | 2011 | 18 | 0.020 |
Why?
|
| 5-Lipoxygenase-Activating Proteins | 1 | 2011 | 3 | 0.020 |
Why?
|
| Prostaglandin-E Synthases | 1 | 2011 | 7 | 0.020 |
Why?
|
| Chromatin | 1 | 2014 | 499 | 0.020 |
Why?
|
| Methotrexate | 1 | 1993 | 339 | 0.020 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2011 | 41 | 0.020 |
Why?
|
| Epoxide Hydrolases | 1 | 2011 | 36 | 0.020 |
Why?
|
| Bacteria | 2 | 2012 | 524 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2011 | 122 | 0.020 |
Why?
|
| Meningeal Neoplasms | 1 | 1993 | 217 | 0.020 |
Why?
|
| Bacterial Infections | 1 | 2013 | 328 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2012 | 553 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1993 | 398 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2012 | 340 | 0.020 |
Why?
|
| Risk Factors | 2 | 2016 | 10953 | 0.020 |
Why?
|
| Cysteine Endopeptidases | 1 | 2010 | 109 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2010 | 92 | 0.020 |
Why?
|
| Ribonuclease P | 1 | 2009 | 9 | 0.020 |
Why?
|
| Aspartate-Ammonia Ligase | 1 | 1989 | 2 | 0.020 |
Why?
|
| Registries | 1 | 2016 | 1610 | 0.020 |
Why?
|
| Pneumonia | 1 | 1993 | 340 | 0.020 |
Why?
|
| Ligases | 1 | 1989 | 35 | 0.020 |
Why?
|
| Haplotypes | 1 | 2011 | 517 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2016 | 6403 | 0.020 |
Why?
|
| Genes, Regulator | 1 | 1989 | 44 | 0.020 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2009 | 84 | 0.020 |
Why?
|
| Lung Diseases | 1 | 1993 | 397 | 0.020 |
Why?
|
| Kidney | 2 | 1993 | 1279 | 0.020 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2008 | 9 | 0.020 |
Why?
|
| Bortezomib | 1 | 2008 | 71 | 0.020 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2008 | 24 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 423 | 0.020 |
Why?
|
| Skin | 2 | 2004 | 539 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2008 | 86 | 0.020 |
Why?
|
| Cell Communication | 1 | 2009 | 188 | 0.020 |
Why?
|
| High Mobility Group Proteins | 1 | 2007 | 33 | 0.020 |
Why?
|
| Clone Cells | 1 | 2008 | 152 | 0.020 |
Why?
|
| Dutasteride | 1 | 2007 | 1 | 0.020 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 1 | 2007 | 2 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2008 | 80 | 0.020 |
Why?
|
| Dimerization | 1 | 2007 | 137 | 0.020 |
Why?
|
| Bias | 1 | 2008 | 148 | 0.020 |
Why?
|
| Expressed Sequence Tags | 1 | 2007 | 76 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 242 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2009 | 418 | 0.020 |
Why?
|
| Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein | 1 | 2006 | 5 | 0.020 |
Why?
|
| SOX9 Transcription Factor | 1 | 2007 | 83 | 0.020 |
Why?
|
| Remission Induction | 1 | 2007 | 306 | 0.020 |
Why?
|
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 1 | 2006 | 13 | 0.020 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2006 | 34 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2007 | 85 | 0.020 |
Why?
|
| Myeloid Cells | 1 | 2007 | 112 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2007 | 86 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2006 | 120 | 0.020 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2006 | 72 | 0.020 |
Why?
|
| Parotid Neoplasms | 1 | 1986 | 21 | 0.020 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2006 | 20 | 0.010 |
Why?
|
| Lymphotoxin-alpha | 1 | 2006 | 7 | 0.010 |
Why?
|
| Microcomputers | 1 | 2006 | 11 | 0.010 |
Why?
|
| Type C Phospholipases | 1 | 2006 | 15 | 0.010 |
Why?
|
| Adolescent | 2 | 2019 | 20802 | 0.010 |
Why?
|
| Caspases | 1 | 2006 | 152 | 0.010 |
Why?
|
| Cells | 1 | 2006 | 20 | 0.010 |
Why?
|
| Sarcoma, Kaposi | 1 | 1987 | 128 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2006 | 234 | 0.010 |
Why?
|
| Software | 1 | 2011 | 733 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2006 | 87 | 0.010 |
Why?
|
| Protein Conformation | 1 | 1987 | 732 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2007 | 759 | 0.010 |
Why?
|
| Contraceptive Agents, Male | 1 | 2006 | 34 | 0.010 |
Why?
|
| Tretinoin | 1 | 2006 | 95 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2008 | 263 | 0.010 |
Why?
|
| Young Adult | 1 | 2019 | 9987 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2006 | 221 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2006 | 183 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2005 | 71 | 0.010 |
Why?
|
| Nuclear Receptor Coactivator 1 | 1 | 2005 | 161 | 0.010 |
Why?
|
| Seminiferous Tubules | 1 | 2004 | 11 | 0.010 |
Why?
|
| GTP Phosphohydrolases | 1 | 2006 | 155 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2006 | 237 | 0.010 |
Why?
|
| Calcinosis | 1 | 1986 | 178 | 0.010 |
Why?
|
| Adenoma | 1 | 1986 | 143 | 0.010 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2004 | 39 | 0.010 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2004 | 52 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 3744 | 0.010 |
Why?
|
| Genistein | 1 | 2004 | 40 | 0.010 |
Why?
|
| Sulfones | 1 | 2004 | 72 | 0.010 |
Why?
|
| Injections, Intradermal | 1 | 2004 | 29 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2004 | 64 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2004 | 142 | 0.010 |
Why?
|
| Flutamide | 1 | 2003 | 22 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2004 | 263 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2004 | 158 | 0.010 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2004 | 92 | 0.010 |
Why?
|
| Phylogeny | 1 | 2006 | 687 | 0.010 |
Why?
|
| Hormone Replacement Therapy | 1 | 2006 | 180 | 0.010 |
Why?
|
| Osteopontin | 1 | 2003 | 54 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1982 | 54 | 0.010 |
Why?
|
| Colchicine | 1 | 1982 | 39 | 0.010 |
Why?
|
| Ketone Bodies | 1 | 1982 | 41 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 2004 | 225 | 0.010 |
Why?
|
| Hepatitis | 1 | 2002 | 56 | 0.010 |
Why?
|
| Cadherins | 1 | 2003 | 182 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2004 | 558 | 0.010 |
Why?
|
| Perfusion | 1 | 1983 | 209 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2004 | 265 | 0.010 |
Why?
|
| Actins | 1 | 2004 | 314 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2002 | 340 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2004 | 510 | 0.010 |
Why?
|
| Leucine | 1 | 1982 | 258 | 0.010 |
Why?
|
| Lysosomes | 1 | 1982 | 264 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2009 | 3781 | 0.010 |
Why?
|
| Infant | 1 | 2016 | 13276 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2000 | 65 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2016 | 15009 | 0.010 |
Why?
|
| Kallidin | 1 | 1999 | 1 | 0.010 |
Why?
|
| Kinins | 1 | 1999 | 1 | 0.010 |
Why?
|
| New York City | 1 | 1999 | 59 | 0.010 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2001 | 252 | 0.010 |
Why?
|
| Receptors, Bradykinin | 1 | 1999 | 3 | 0.010 |
Why?
|
| Phosphatidylinositols | 1 | 1999 | 30 | 0.010 |
Why?
|
| Phorbol Esters | 1 | 1999 | 21 | 0.010 |
Why?
|
| Hydrolysis | 1 | 1999 | 140 | 0.010 |
Why?
|
| Europe | 1 | 1999 | 360 | 0.010 |
Why?
|
| Endothelin-Converting Enzymes | 1 | 1998 | 1 | 0.010 |
Why?
|
| Endothelin-3 | 1 | 1998 | 1 | 0.010 |
Why?
|
| Receptor, Endothelin B | 1 | 1998 | 6 | 0.010 |
Why?
|
| Receptor, Endothelin A | 1 | 1998 | 11 | 0.010 |
Why?
|
| Receptors, Endothelin | 1 | 1998 | 9 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 1989 | 252 | 0.010 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 1998 | 30 | 0.010 |
Why?
|
| Cell Count | 1 | 1998 | 212 | 0.010 |
Why?
|
| Biological Availability | 1 | 1998 | 136 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1999 | 589 | 0.010 |
Why?
|
| Metalloendopeptidases | 1 | 1998 | 101 | 0.010 |
Why?
|
| Tensins | 1 | 1997 | 3 | 0.010 |
Why?
|
| Neocortex | 1 | 1998 | 75 | 0.010 |
Why?
|
| Phosphotyrosine | 1 | 1997 | 30 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2001 | 469 | 0.010 |
Why?
|
| Frameshift Mutation | 1 | 1997 | 201 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1997 | 356 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1997 | 452 | 0.010 |
Why?
|
| Point Mutation | 1 | 1997 | 332 | 0.010 |
Why?
|
| Child | 1 | 2016 | 26181 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 1995 | 129 | 0.010 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 1995 | 67 | 0.010 |
Why?
|
| Cryptococcus neoformans | 1 | 1993 | 20 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1998 | 943 | 0.010 |
Why?
|
| Psoriasis | 1 | 1993 | 48 | 0.010 |
Why?
|
| Myocardium | 1 | 1997 | 858 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 1993 | 422 | 0.010 |
Why?
|
| Incidence | 1 | 1999 | 3314 | 0.010 |
Why?
|
| Electrocardiography | 1 | 1997 | 972 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 1997 | 1177 | 0.010 |
Why?
|
| Fibroblast Growth Factor 4 | 1 | 1990 | 4 | 0.010 |
Why?
|
| Antibodies, Neoplasm | 1 | 1990 | 55 | 0.000 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 1989 | 61 | 0.000 |
Why?
|
| Asparagine | 1 | 1989 | 22 | 0.000 |
Why?
|
| Restriction Mapping | 1 | 1989 | 167 | 0.000 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 1989 | 77 | 0.000 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 1989 | 77 | 0.000 |
Why?
|
| Transformation, Genetic | 1 | 1987 | 27 | 0.000 |
Why?
|
| Bacteriophage lambda | 1 | 1987 | 26 | 0.000 |
Why?
|
| Bacteriophages | 1 | 1989 | 101 | 0.000 |
Why?
|
| DNA, Recombinant | 1 | 1987 | 71 | 0.000 |
Why?
|
| Brain Neoplasms | 1 | 1997 | 1306 | 0.000 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1987 | 330 | 0.000 |
Why?
|
| Cytoplasmic Granules | 1 | 1986 | 50 | 0.000 |
Why?
|
| Organoids | 1 | 1986 | 300 | 0.000 |
Why?
|
| Phenylalanine | 1 | 1982 | 131 | 0.000 |
Why?
|